ea0029p1435 | Pituitary Clinical | ICEECE2012
Zamuner M. Mijares
, Sanchez-Pacheco M.
, Tardon
, Gotarredona J. Serrano
, Perez O. Moreno
, Avella G. Negueruela
, Vidal R. Cerezo
, Ortiga R. Sanchez
, Alfonso A. Pico
Introduction: Hyponatremia is the most common electrolyte disorder in hospitalized patients. SIADH is characterized by euvolemic hyponatremia with sodium and urine osmolality inappropriately high. The selective antagonist of the vasopressin V2 receptor (tolvaptan) helps to eliminate water free of solute (aquaresis), being effective in treating this condition.Objetive: Evaluate the efficacy and safety of tolvaptan in the treatment of SIADH.<p class="a...